Literature DB >> 2543282

In vitro synergism between daptomycin and fosfomycin against Enterococcus faecalis isolates with high-level gentamicin resistance.

L B Rice1, G M Eliopoulos, R C Moellering.   

Abstract

Daptomycin and fosfomycin are two agents which inhibit different steps in peptidoglycan synthesis. We studied the in vitro activities of these drugs, alone and in combination, by time-kill techniques against 21 clinical isolates of Enterococcus (Streptococcus) faecalis demonstrating high-level resistance to gentamicin. Combinations of fosfomycin and daptomycin exhibited synergistic bactericidal activity (100-fold decrease in CFU per milliliter at 24 h compared with daptomycin alone) against all strains (mean +/- standard deviation of increment in killing = 2.7 +/- 0.7 log10 CFU/ml). In a subgroup of strains against which daptomycin (5 micrograms/ml) alone was bactericidal (greater than 3 log10 killing), synergistic activity was demonstrable only when the concentration of daptomycin was lowered to 0.25 to 0.5 microgram/ml. A 50% dilution of human serum diminished the bactericidal activity of daptomycin alone at 24 h but did not affect killing observed with the daptomycin-fosfomycin combination. The inhibition of peptidoglycan synthesis by the combination was greater than the inhibition observed with either drug alone. The combination of daptomycin and fosfomycin exhibited consistent synergistic bactericidal activity against strains of E. faecalis possessing high-level resistance to gentamicin. This synergism may be the result of sequential inhibition of early steps in peptidoglycan synthesis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2543282      PMCID: PMC172462          DOI: 10.1128/AAC.33.4.470

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Enterococcal endocarditis.

Authors:  S Wessler
Journal:  JAMA       Date:  1968-06-03       Impact factor: 56.272

2.  In vitro activity and mechanism of action of A21978C1, a novel cyclic lipopeptide antibiotic.

Authors:  G M Eliopoulos; C Thauvin; B Gerson; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

3.  Experimental endocarditis and fosfomycin.

Authors:  A Rodríguez; M V Vicente; T Olay
Journal:  Drugs Exp Clin Res       Date:  1985

4.  A simple method for following the fate of alanine-containing components in murein synthesis in Escherichia coli.

Authors:  E J Lugtenberg; P G de Haan
Journal:  Antonie Van Leeuwenhoek       Date:  1971       Impact factor: 2.271

5.  Daptomycin (LY146032) treatment of experimental enterococcal endocarditis.

Authors:  L M Bush; J A Boscia; D Kaye
Journal:  Antimicrob Agents Chemother       Date:  1988-06       Impact factor: 5.191

6.  Enterococci from Bangkok, Thailand, with high-level resistance to currently available aminoglycosides.

Authors:  B E Murray; J Tsao; J Panida
Journal:  Antimicrob Agents Chemother       Date:  1983-06       Impact factor: 5.191

7.  Fosfomycin in the treatment of bacterial infections: summary of clinical trials in Japan.

Authors:  R Fujii
Journal:  Chemotherapy       Date:  1977       Impact factor: 2.544

8.  Susceptibility of enterococci and Listeria monocytogenes to N-Formimidoyl thienamycin alone and in combination with an aminoglycoside.

Authors:  G M Eliopoulos; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1981-05       Impact factor: 5.191

9.  High-level resistance to gentamicin in clinical isolates of enterococci.

Authors:  B D Mederski-Samoraj; B E Murray
Journal:  J Infect Dis       Date:  1983-04       Impact factor: 5.226

10.  The mechanism of action of fosfomycin (phosphonomycin).

Authors:  F M Kahan; J S Kahan; P J Cassidy; H Kropp
Journal:  Ann N Y Acad Sci       Date:  1974-05-10       Impact factor: 5.691

View more
  16 in total

1.  Influence of high-level gentamicin resistance and beta-hemolysis on susceptibility of enterococci to the bactericidal activities of ampicillin and vancomycin.

Authors:  E Cercenado; G M Eliopoulos; C B Wennersten; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

Review 2.  Screening and treatment of infections caused by resistant enterococci.

Authors:  D J Herman; D N Gerding
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

3.  Bactericidal activity of daptomycin against vancomycin-resistant Enterococcus faecium in an in vitro pharmacokinetic model.

Authors:  E Bingen; C Doit; N Lambert-Zechovsky; M Tod; O Petitjean; F Bourgeois; P Mariani-Kurkdjian
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-12       Impact factor: 3.267

Review 4.  Plasmid-encoded fosfomycin resistance.

Authors:  J E Suárez; M C Mendoza
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

Review 5.  Fosfomycin: an old, new friend?

Authors:  M Popovic; D Steinort; S Pillai; C Joukhadar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-11-14       Impact factor: 3.267

6.  Altering the proclivity towards daptomycin resistance in methicillin-resistant Staphylococcus aureus using combinations with other antibiotics.

Authors:  Andrew D Berti; Justine E Wergin; Gary G Girdaukas; Scott J Hetzel; George Sakoulas; Warren E Rose
Journal:  Antimicrob Agents Chemother       Date:  2012-07-16       Impact factor: 5.191

Review 7.  The life and times of the Enterococcus.

Authors:  B E Murray
Journal:  Clin Microbiol Rev       Date:  1990-01       Impact factor: 26.132

8.  Synergy of fosfomycin with other antibiotics for Gram-positive and Gram-negative bacteria.

Authors:  Antonia C Kastoris; Petros I Rafailidis; Evridiki K Vouloumanou; Ioannis D Gkegkes; Matthew E Falagas
Journal:  Eur J Clin Pharmacol       Date:  2010-02-26       Impact factor: 2.953

Review 9.  A Review of Combination Antimicrobial Therapy for Enterococcus faecalis Bloodstream Infections and Infective Endocarditis.

Authors:  Maya Beganovic; Megan K Luther; Louis B Rice; Cesar A Arias; Michael J Rybak; Kerry L LaPlante
Journal:  Clin Infect Dis       Date:  2018-07-02       Impact factor: 9.079

10.  Utilization of time-kill kinetic methodologies for assessing the bactericidal activities of ampicillin and bismuth, alone and in combination, against Helicobacter pylori in stationary and logarithmic growth phases.

Authors:  P E Coudron; C W Stratton
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.